Clinical trial
S0536: Cetuximab, Paclitaxel, Carboplatin, and Bevacizumab in Treating Patients…
NCT00368992 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00368992 |
|---|---|
| Title | S0536: Cetuximab, Paclitaxel, Carboplatin, and Bevacizumab in Treating Patients With Advanced Non-Small Cell Lung Cancer |
| Official title | A Phase II Trial of Combination Carboplatin, Paclitaxel, Cetuximab and Bevacizumab (NSC-704865) Followed By Cetuximab and Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer, Bronchoalveolar Cell Lung Cancer, Large Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer, Squamous Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer |
| Intervention type | Biological, Drug |
| Interventions | cetuximab, paclitaxel, bevacizumab |
| Enrollment | 110 |
| Start date | Aug 1, 2006 |
| Primary completion | Oct 1, 2010 |
| Completion | Oct 1, 2010 |
| First posted | Aug 29, 2006 |
| Last update posted | Sep 14, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: